What Is My IP Worth? Patent Valuation and Licensing in India

An investor's diligence checklist lands in your inbox. Item 14: "Please provide a valuation of the company's registered intellectual property." You have eleven granted Indian patents, six years of renewal fees paid on all of them, and absolutely no idea what to write. Nobody has ever explained how patent valuation in India actually works, or who is supposed to do it.

That gap is wider than the filing statistics suggest. India recorded 110,375 patent applications in 2024-25. What is rarely published is how few of those rights ever produce a rupee: India paid US$16.26 billion in charges for the use of intellectual property in 2024 and received back US$1.73 billion (World Bank balance-of-payments data). On a net basis we are a licensee country, not a licensor one.

This guide covers how patent valuation works in India, who may legally sign the report, how licences and assignments differ in law, how royalties are structured so they get paid, and what a buyer checks before deciding your patent is worth anything.

Quick answer

There is no single number. Value depends on the purpose of the valuation and the basis that purpose requires — a fundraise, a tax position, a licence negotiation and a damages claim can all produce different answers from the same patent, and all four can be right.

Indian valuers use three approaches. The cost approach is the weakest but has narrow uses. The market approach is limited here because Indian patent deal data is scarce and mostly private. The income approach — usually relief-from-royalty — is what gets used and what diligence teams expect.

Where the valuation supports a share issue under Section 62 of the Companies Act, 2013, a scheme or an insolvency process, it must be signed by a registered valuer under Section 247. Everywhere else it is a commercial document, and quality varies enormously.

Worth what, to whom, for what purpose

Before anyone opens a spreadsheet: what is the valuation for, and what basis of value does that purpose require. ICAI Valuation Standard 102 exists for this reason, and getting it wrong is the commonest defect in Indian IP valuation reports.

The same patent can be worth ₹40 lakh in one row and ₹4 crore in another without anyone having lied. If someone quotes you a value without first asking what it is for, that tells you something about the work that follows.

Why your balance sheet says nothing

Under Ind AS 38, expenditure in the research phase of an internal project cannot be recognised as an asset at all. Development-phase spending can be capitalised only if all six conditions in the standard are met. It goes further: internally generated brands, mastheads, publishing titles and customer lists "shall not be recognised as intangible assets". The revaluation model needs fair value measured against an active market, which effectively does not exist for patents because patents are unique.

So a company that buys a patent carries it at cost. A company that invents one carries nothing but the R&D expense. The more innovative company looks poorer on paper. That is not an error to fix — it is why a separate valuation exercise exists at all.

The three approaches

ICAI Valuation Standard 302 (Intangible Assets) and IVS 210 (Intangible Assets) recognise the same three approaches.

Cost approach — weakest, still occasionally right

What it cost to create (historical cost), or what it would cost to recreate the utility (replacement cost) or the asset itself (reproduction cost). Illustration: ₹1.8 crore of R&D, ₹6 lakh of prosecution across three jurisdictions and ₹2 lakh of renewals gives a historical cost of about ₹1.88 crore.

That figure measures effort, not outcome. A ₹5 crore programme that produced a patent nobody wants is worth less than a ₹4 lakh patent reading squarely on a product selling at scale. Cost ignores remaining term, claim strength and whether anyone is infringing.

It remains the right tool for insurance cover, internal transfer between group entities where no external market exists, and very early-stage assets with no revenue history, where an income projection would be invention rather than analysis. Say which, and label the output a cost figure rather than a value.

Market approach — the honest Indian problem

Value by reference to comparable transactions; IVS 210 calls this the guideline transactions method. Illustration: three comparable process patents transacting at ₹2.2, ₹2.9 and ₹3.4 crore support a ₹2.5–3 crore indication.

The trouble is that those data points usually do not exist here. Assignments recorded under Section 69 name the parties but not the price. Form 27 working statements, since the Patents (Amendment) Rules, 2024, require only whether the invention was worked — no financial detail. Indian corporate licence terms are almost never public, and commercial royalty databases are dominated by US and European deals needing heavy adjustment.

So in India the market approach is a sense-check on an income answer, not a primary method. If a report presents it as primary, ask where the comparables came from and what adjustments were made.

Income approach — what actually gets used

Both standards name the same family: relief-from-royalty, multi-period excess earnings, with-and-without (premium profit), greenfield and distributor. Three matter for a typical Indian patent owner:

• Incremental-cash-flow DCF — clean in principle, hard in practice, because attributing cash flow to one patent inside a working business invites argument.
• With-and-without — model the business as it is, then again assuming the patent does not exist and competitors may copy. The difference is the patent's contribution, and it is an excellent cross-check on a royalty rate.
• Relief-from-royalty — value the asset as the royalty you would pay if you did not own it. The workhorse.

Relief-from-royalty, done properly

The wrong version is "pick a rate, multiply by revenue, multiply by years left". That is not the method. Working from the inputs IVS 210 requires, a defensible calculation needs:

• A revenue projection for the asset, not the company — sales of products on which the independent claims read. Not group turnover.
• A royalty rate derived from evidence — comparable licences adjusted for differences, or a profit split grounded in the product's actual margins.
• Expenses a licensee would still bear on the licensed asset — usually small for a patent, but the standard requires you to consider them.
• A tax rate, because the relevant saving is the after-tax royalty. Skipping this overstates value by roughly a quarter for an Indian corporate taxpayer.
• A remaining economic life, often shorter than the legal term. Eleven years left on the register can mean five years of commercial relevance if a design-around is visible.
• A discount rate appropriate to the asset — normally above the company's WACC, because a single patent carries technology and validity risk the whole business does not.
• A tax amortisation benefit where the basis of value requires one. IVS 210 is explicit that in the income approach a TAB must be calculated and included if appropriate, whereas the market and cost approaches already embed it.

Two consistency rules underlie all of this. The rate and the base must match — a rate observed on net sales cannot be applied to gross invoice value or a component price. And after-tax cash flows need an after-tax discount rate.

Worked example

Hypothetical illustration, not a MYCrave client matter. The figures are constructed to show the mechanics.

A Vadodara pump manufacturer holds an Indian patent, filed March 2019 and granted 2022, over a shaft-seal arrangement that reduces leakage. It sells the patented models itself and is weighing a licence to a non-competing manufacturer.

Rate cross-check (with-and-without). EBIT margin on the covered models is about 18%. Without the patented seal the company estimates it would settle near 13%, competing on price against copyable products. That gives roughly 5 percentage points of margin attributable to the patent — the ceiling a rational licensee would pay. Negotiating for a share of that surplus lands in the 3–4% band, so we take 3.5%. Evidence-led, not a rule of thumb.

Before any tax amortisation benefit, the indication is about ₹4.3 crore. A TAB, where the basis of value calls for one, would lift it; its size depends on the depreciation rate available and the discount rate, and it is among the most commonly omitted steps.

Now change one assumption at a time.

Across individually defensible assumptions the answer runs from roughly ₹2.2 crore to ₹6.2 crore. That spread is the honest output. A report giving you a single number to the rupee, with no sensitivity table, is telling you less than it appears to.

The 25% rule

For decades negotiators used a shortcut: the licensee keeps 75% of the profit on the licensed product, the licensor takes 25%. It was fast, sounded fair, and produced numbers roughly in the right postcode for manufacturing licences.

It is no longer defensible. In Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292 (Fed. Cir., 4 January 2011), the US Court of Appeals for the Federal Circuit held the 25% rule of thumb to be "a fundamentally flawed tool for determining a baseline royalty rate", inadmissible under Daubert because it fails to tie the royalty to the facts — it says nothing about the particular technology, parties or negotiation.

Indian valuers still quote it. If it appears in a report you paid for, ask what evidence supports that split for your asset, in your industry, at your stage. Use instead a with-and-without margin analysis on the actual product, comparable licences adjusted for differences, or a profit split on disclosed cost and margin data — with a factor checklist (remaining term, exclusivity, territory, field of use, the licensee's alternatives) used to adjust an evidence-based rate, never to generate one.

Who can legally sign a valuation

Three frameworks operate at once.

ICAI Valuation Standards, 2018 — eight standards issued 10 June 2018, effective for reports issued on or after 1 July 2018, including VS 302 (Intangible Assets). Mandatory for valuations under the Companies Act, 2013 and recommendatory for ICAI members working under other statutes, pending notified Central Government standards.

IVS 210 Intangible Assets — part of the International Valuation Standards, current edition effective 31 January 2025. Not law in India, but it is what an international acquirer expects, and it is more detailed than VS 302 on method inputs.

Section 247 of the Companies Act, 2013 with the Companies (Registered Valuers and Valuation) Rules, 2017 (in force 18 October 2017), administered by IBBI.

Here is the point most owners have never been told. Annexure IV to the 2017 Rules notifies three asset classes: Land and Building, Plant and Machinery, and Securities or Financial Assets. There is no notified asset class for intangible assets or intellectual property. A patent valuation for company-law purposes is therefore signed by a registered valuer in the Securities or Financial Assets class — a qualification certifying competence in valuation technique, not in reading a patent claim. Which is why better Indian reports carry separate patent-side input on claim scope, validity risk and remaining commercial life.

If you are issuing shares for IP, commission the report before the board resolution.

Licence or assignment

An assignment transfers ownership. A licence grants permission while ownership stays with you.

For patents, three provisions do the work.

Section 68 of the Patents Act, 1970: an assignment, mortgage, licence or creation of any other interest is not valid unless in writing and reduced to "a document embodying all the terms and conditions governing their rights and obligations", duly executed. A term-sheet email is not an assignment, and a side understanding outside the document is not part of it.

Section 69: the acquirer applies to the Controller in Form 16 for entry in the register. Government fee ₹1,600 per patent for a natural person, startup, small entity or educational institution on e-filing, ₹8,000 for others (₹1,750 and ₹8,800 physical). Section 69(4) requires the instrument itself to be supplied, though a licensor or licensee may ask that licence terms not be open to public inspection.

Section 69(5) is the one that bites. A document with no entry in the register is not admitted in evidence of title, unless the Controller or the court directs otherwise for reasons recorded in writing. An unrecorded assignee can find itself unable to prove its own title at the moment it most needs to — which is why chain-of-title and recordal work belongs before a data room, not during one.

Section 109 gives an exclusive licensee the same right to sue for infringement as the patentee, for infringements after the licence date, with the patentee joined as a defendant if not a plaintiff. A non-exclusive licensee has no such right. If enforcement matters to your licensee, that one word changes what they are buying.

Trade marks work differently. Under Chapter V of the Trade Marks Act, 1999, Section 37 gives the proprietor power to assign, Section 38 makes registered marks assignable with or without goodwill, Sections 40–42 restrict assignments creating confusing parallel or geographically split rights, and Section 45 requires the person entitled to apply to register their title. On licensing, Section 2(1)(r)(ii) treats use by someone who is not a registered user as "permitted use" if it is by consent in a written agreement, and Section 48(2) deems permitted use to be use by the proprietor — which protects the mark against non-use cancellation. So registered-user recordal under Section 49 is optional. But Section 52 lets a registered user sue in its own name and Section 53 denies that right to a Section 2(1)(r)(ii) permitted user. Recordal buys standing; a written licence buys non-use protection.

The risk of sitting on an unworked patent

A commercial argument for licensing that rarely appears in Indian content.

Under Section 84, at any time after three years from grant, any person interested may apply for a compulsory licence on three grounds: the reasonable requirements of the public are not satisfied, the invention is not available at a reasonably affordable price, or it is not worked in the territory of India. If one is granted, Section 90(1)(i) requires the Controller to settle a royalty that is reasonable having regard to the nature of the invention and what the patentee spent making it. Read that from the owner's side: the Controller sets the rate, not you. Under Section 85, two years after a compulsory licence the patent can be revoked for continued non-working, and Section 92 allows the Central Government to notify compulsory licensing in a national emergency, in circumstances of extreme urgency, or for public non-commercial use.

Compulsory licences are rare — the Natco Pharma licence over Bayer's sorafenib patent, granted March 2012, is the well-known instance — and the realistic risk for most portfolios is low. But the exposure is real in public health, agriculture and any area of visible unmet demand, and the general point holds: a licence you negotiate beats a licence someone else writes for you.

A disclosure obligation attaches. Under Section 146(2) and Rule 131, every patentee and every licensee must file a statement of working in Form 27, since 2024 once every three financial years and with no government fee. The current cycle covers FY 2023-24 to FY 2025-26 and is due by 30 September 2026 for patents granted on or before 31 March 2023. Filing by the patentee does not discharge the licensee's obligation. Section 122, as amended by the Jan Vishwas (Amendment of Provisions) Act, 2023, now attaches monetary penalties rather than imprisonment to a failure or a false statement. The renewal and post-grant compliance guide sets out that calendar alongside the annuities.

Royalty structures that get paid

The structure decides whether money arrives. Settle it before arguing about the rate.

On published benchmarks. A widely cited study using RoyaltySource Licensing Economics Review data — 3,015 transactions across roughly 15 industries over 21 years — reported a mean royalty rate of 7.0% and a median of 5.0%. Treat it as orientation only: the dataset is predominantly US and European, and now dated. We could not verify any published sector-level royalty benchmark specific to Indian patent transactions. Rather than reproduce a range invented elsewhere, the honest position is that Indian rates have to be built from the product's own economics, as the with-and-without cross-check does.

One Indian judicial data point is worth knowing. In Telefonaktiebolaget LM Ericsson v. Lava International Ltd. (2024 SCC OnLine Del 2497, 28 March 2024), the Delhi High Court decreed damages of ₹244,07,63,990 with interest, computed by reference to the royalty the patentee would have earned under a licence on fair, reasonable and non-discriminatory terms. A court will build a royalty from evidence — and a patentee who never licensed still had to prove what a licence was worth.

The clauses that decide whether a royalty is ever actually paid:

• The royalty base. Define "net sales" precisely: gross invoice value less GST and other indirect taxes, trade discounts actually allowed, documented returns, and separately stated freight and insurance. Nothing else — every further deduction the licensee proposes is a rate cut in disguise. Where the licensed feature sits inside a larger product, say whether the base is the whole product or a defined component.
• Audit rights. An independent chartered accountant, on notice, once a year, with the licensee bearing the cost if an understatement above a stated threshold is found. Without this, the royalty is whatever the licensee says it is.
• Reporting cadence. Quarterly statements in a format attached as a schedule, within a fixed number of days of quarter end, payment due the same date.
• Sub-licensing and improvements. Do not rely on silence. State the share of sub-licence income payable and whether sub-licences survive termination; and say who owns licensee improvements. Draft any grant-back narrowly.
• Termination and survival. Breach with a cure period, insolvency, change of control — then the sell-off period, return of technical information, survival of accrued royalties, and who pays renewals, files Form 27 and funds enforcement.

Tax, GST and FEMA

This is where a well-negotiated rate quietly loses a fifth of its value. The Income-tax Act, 2025 came into force on 1 April 2026 and replaces the Income-tax Act, 1961 — that much is settled, and the CBDT's own transition FAQs say so.

The renumbering is the part to handle carefully. The substantive rules below are unchanged by it; what changed is where they sit. The 2025 Act section numbers given here are our reading of the new numbering and have not been checked against a CBDT concordance, so the familiar 1961 Act provision is named alongside each one. Until your advisers confirm the new numbers, cite both in anything that has to stand up — a contract, a withholding certificate, a return.

Royalty to a non-resident. Under Section 207 (formerly Section 115A), royalty and fees for technical services paid by an Indian payer to a non-resident are taxed at 20%, plus surcharge and cess — an effective withholding rate around 20.8% to 21.84%. That is the position after the Finance Act, 2023 doubled the rate from 10%. A tax treaty may give a lower rate, often 10% or 15%, applied without surcharge and cess; claiming it needs a tax residency certificate and the prescribed declaration under Section 159 (formerly Section 90(4)). If you are the Indian licensor receiving royalty from abroad, the mirror-image point applies.

The patent box — valuable and almost unpublicised. Section 194 (formerly Section 115BBF) taxes royalty from a patent developed and registered in India at 10%, for a person resident in India who is a patentee — a true and first inventor entered on the register. "Developed" requires at least 75% of the expenditure on the invention to have been incurred in India. No deduction for expenditure is available against that income. The option must be exercised by the return due date, and failing to comply in any of the five succeeding tax years costs the benefit for five years after that. Under the 1961 Act the option went in Form 3CFA; confirm the corresponding procedure under the 2025 Act for the current year.

One caution. A domestic company that opted into the concessional corporate regime (Section 115BAA under the old Act) should take advice before assuming the patent box still applies. The Delhi Bench of the ITAT in Maharishi Education Corporation (P.) Ltd. v. ITO read the concessional-regime provision as overriding special rates elsewhere in the same Chapter. That case was about capital gains rates, not the patent box, so applying its reasoning here is an inference rather than authority — but it is the inference a careful assessing officer might also draw. The point is unsettled; do not structure around it either way without a written opinion.

GST. Since 1 October 2021, under Notification No. 06/2021-Central Tax (Rate) dated 30 September 2021, "temporary or permanent transfer or permitting the use or enjoyment of Intellectual Property (IP) right" is taxed at 18%, unifying rates that were previously split between IT software and other IPR. The 2025 rate rationalisation (notifications dated 17 September 2025, effective 22 September 2025) restructured a great many entries — confirm the current one for your supply before quoting a figure in a contract. The goods-versus-services classification wrinkle for permanent transfers also affects place of supply and documentation.

FEMA. Royalty, lump-sum technology transfer fees and payments for use of a trademark or brand name are on the automatic route with no percentage caps. The old ceilings — 5% on domestic sales, 8% on exports, 1% and 2% for trademark use, and a US$2 million lump-sum limit — went with the DIPP liberalisation of December 2009, given effect by RBI A.P. (DIR Series) Circular No. 52 dated 13 May 2010. Normal remittance documentation still applies, including Form 15CA and, where required, Form 15CB.

Stamp duty on an assignment deed is a State subject; duty in Maharashtra differs from Gujarat or Karnataka. An insufficiently stamped instrument creates evidentiary problems later, so check before execution.

What makes a patent attractive

Roughly the order a buyer or licensee works through it:

Where Indian portfolios most often fail: rows 1 and 5. Claims drafted around a research disclosure rather than a commercial product, and chain of title never recorded because nobody thought Section 69 mattered until a diligence lawyer asked.

How MYCrave can help

MYCrave Consultancy & Services runs its commercialization work through IP BANK India, one of three pillars alongside protection and education. The site records 11,000+ inventions and novel ideas managed and, among named outcomes, a ₹42 lakh copyright transfer for an Android application.

A scope note first, because it matters: a statutory valuation report for a share issue, a scheme or an insolvency process must be signed by a registered valuer under the 2017 Rules. MYCrave's role is the IP-side work that report depends on, and the commercialization route that follows.

Concretely:

• Portfolio triage — reading granted claims against products actually in the market, and saying which patents are commercial assets and which are renewal-fee liabilities.
• Chain-of-title cleanup — inventor assignments, name changes and Section 69 recordal in Form 16, before a buyer's lawyer finds the gap.
• Claim charts and evidence of use — turning "we have a patent" into "here is who is practising it".
• Valuation inputs — remaining commercial life, design-around cost, validity risk and territorial coverage, in a form a registered valuer can rely on.
• Licence and assignment structuring — royalty base, audit rights, reporting format, minimums, improvements, termination — and Form 27 compliance for the current cycle, for the patentee and each licensee.
• Deal routing through IP BANK India, including institutional portfolios where the inventor has moved on.

Technical and prosecution work is led by a Registered Patent Agent (No. 5509), across a record of 22,000+ IPR filings. Tax structuring and the statutory valuation signature come from your chartered accountant and a registered valuer; MYCrave works alongside them, not in place of them.

A closing warning drawn from the same work: the two things that most often stop an Indian IP deal are claims that read on nobody's product and a chain of title nobody recorded. Both are cheaper to fix now than in a data room.

Start with the question, not the number

"What is my IP worth" has no answer until you say what it is for. Once you do, patent valuation in India stops being mysterious: the arithmetic is tractable, the range is honest, and the number becomes something you can defend in a negotiation rather than something you hope nobody asks about.

Three things are worth doing this month whatever you decide about a formal valuation. Pull your granted claims and check whether they read on a product someone is selling. Check that every assignment in your chain of title has been recorded under Section 69. And if you hold any patent granted on or before 31 March 2023, diary the Form 27 statement due by 30 September 2026.

Frequently asked questions

Keep reading